Trial Profile
A Phase 2, Double-masked, Randomized, Placebo-controlled, Dose-response Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 Ophthalmic Solution 0.05%, 0.1% and 0.25% in Patients With Elevated Intraocular Pressure
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 May 2014
Price :
$35
*
At a glance
- Drugs Verosudil (Primary)
- Indications Glaucoma; Ocular hypertension
- Focus Therapeutic Use
- Sponsors Aerie Pharmaceuticals
- 02 May 2014 New trial record